IDDI organized a webinar on THE NEED FOR BETTER CLINICAL ENDPOINTS : TOWARDS A MORE EFFICIENT DRUG DEVELOPMENT IN ONCOLOGY

The increasing number of potential targeted therapies puts a pressure on the ability to evaluate the efficacy of candidate treatments in a fast way. A key element in the evaluation process is the use of sensitive and relevant clinical endpoints.

  • This webinar reviewed  a range of established and novel endpoints that could be considered for use in the cancer trials. The speakers discussed potential benefits and risks of the use of the different endpoints.
  • The increasing number of potential targeted therapies puts a pressure on the ability to evaluate the efficacy of candidate treatments in a fast way. A key element in the evaluation process is the use of sensitive and relevant clinical endpoints.
  • This webinar reviewed  a range of established and novel endpoints that could be considered for use in the cancer trials. The speakers discussed potential benefits and risks of the use of the different endpoints.
Tomasz Burzykowski, Ph.D.

Tomasz Burzykowski, Ph.D.

VP Research

Everardo Saad, M.D.

Everardo Saad, M.D.

Medical Director

Back to Resources

View the Presentation

Trust Your Data to IDDI

Start Now